HTG Molecular Diagnostics, Inc. a commercial stage life sciences company, focuses on the precision medicine. The company offers instrumentation (or platforms); consumables comprising assay kits; and software analytics that automate sample processing and profiles various molecular targets. Its platforms generate a molecular profiling library for detection using next-generation sequencing. The company's assay product offerings include HTG EdgeSeq oncology biomarker panel; HTG EdgeSeq immuno-oncology assay; HTG EdgeSeq DLBCL Cell of Origin Assay; HTG EdgeSeq PATH Assay; HTG EdgeSeq miRNA Whole-Transcriptome Assay; HTG EdgeSeq DLBCL Cell of Origin Assay EU; HTG EdgeSeq ALKPlus Assay EU; HTG EdgeSeq EGFR, KRAS and BRAF Mutation Assay; and HTG EdgeSeq Precision Immuno-Oncology Panel. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. HTG Molecular Diagnostics, Inc. distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. The company has a collaboration agreement with Bristol-Myers Squibb for the development of custom RUO assays; governing agreement with QIAGEN Manchester Limited; development and professional services agreement with Invetech PTY Ltd; and an agreement with Illumina, Inc. for the development of nuclease-protection-based RNA or DNA profiling tests. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona.
Industry, Sector and Symbol
Industry Analytical instruments
Sub-IndustryN/A
SectorMedical
Phone877-289-2615
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$21.50 million
Profitability
Miscellaneous
Employees107
Next Earnings Date8/6/2019 (Estimated)
OptionableOptionable
HTG Molecular Diagnostics (NASDAQ:HTGM) Frequently Asked Questions
What is HTG Molecular Diagnostics' stock symbol?
HTG Molecular Diagnostics trades on the NASDAQ under the ticker symbol "HTGM."
How were HTG Molecular Diagnostics' earnings last quarter?
HTG Molecular Diagnostics Inc (NASDAQ:HTGM) posted its quarterly earnings data on Thursday, May, 9th. The medical research company reported ($0.19) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.17) by $0.02. The medical research company earned $3.20 million during the quarter, compared to analyst estimates of $2.77 million. HTG Molecular Diagnostics had a negative return on equity of 75.50% and a negative net margin of 80.03%. View HTG Molecular Diagnostics' Earnings History.
When is HTG Molecular Diagnostics' next earnings date?
What guidance has HTG Molecular Diagnostics issued on next quarter's earnings?
HTG Molecular Diagnostics updated its FY 2019 earnings guidance on Thursday, March, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $23-28 million, compared to the consensus revenue estimate of $29.6 million.HTG Molecular Diagnostics also updated its Q1 2019 guidance to EPS.
What price target have analysts set for HTGM?
5 analysts have issued 1-year target prices for HTG Molecular Diagnostics' stock. Their predictions range from $5.00 to $8.00. On average, they anticipate HTG Molecular Diagnostics' share price to reach $6.75 in the next twelve months. This suggests a possible upside of 209.6% from the stock's current price. View Analyst Price Targets for HTG Molecular Diagnostics.
What is the consensus analysts' recommendation for HTG Molecular Diagnostics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for HTG Molecular Diagnostics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for HTG Molecular Diagnostics.
What are Wall Street analysts saying about HTG Molecular Diagnostics stock?
Here are some recent quotes from research analysts about HTG Molecular Diagnostics stock:
- 1. According to Zacks Investment Research, "HTG Molecular Diagnostics, Inc. is engaged in developing and marketing a technology platform which consists of instrumentation, consumables and software analytics for sample profiling applications including tumor profiling, molecular diagnostic testing and biomarker development. Its products include HTG Edge System, HTG Edge Assays and HTG Assay Direct. HTG Molecular Diagnostics, Inc. is headquartered in Tucson, Arizona. " (5/17/2019)
- 2. Canaccord Genuity analysts commented, "We reiterate our $5 price target. Q1 beat. Q1/19 revs of $3.2M (-23% Y/Y) beat our $2.6M and the guide of $2.5-3.0M. HTG’s core product revenue of $2.7M (+54%) beat our 1.7ME, and was offset by research revenue of just $0.5M (-78% Y/Y) which was down as two of its active PDP programs are on hold" or paused". Recall that collaboration revenues are lumpy, and HTG drove +56% growth in pharma (PDP) revenue in FY’18. LPS of ($0.19) beat our ($0.26) on lighter spend. HTG now holds $25M of cash on its balance sheet. ILMN amendment. In April, HTG amended its IVD test development agreement with Illumina, for the development and commercialization of RNA or DNA profiling tests for use with ILMN’s MiSeqDx sequencer in oncology diagnostics." (5/14/2019)
- 3. Cantor Fitzgerald analysts commented, "We reaffirm our OW rating and think HTG’s EdgeSeq offers an attractive workflow solution that addresses key challenges in many existing molecular profiling technologies on the market. We view RNA-based panels as well-positioned to capitalize on trends in biomarker development, including faster turnaround time, lower sample-volume requirement, and next-gen sequencing (NGS)- based testing. We think shares of HTG will be rewarded with consistent product and service revenue acceleration along with a demonstrated growing pipeline of exclusive revenue-generating PDPs." (2/20/2019)
- 4. HC Wainwright analysts commented, "Our price target is derived from a market value of the firm at $222M excluding debt. This includes a discounted cash flow analysis based asset value at $231M for the HTG EdgeSeq platform, with a 15% discount rate and 0% terminal growth rate." (12/19/2018)
Has HTG Molecular Diagnostics been receiving favorable news coverage?
Media coverage about HTGM stock has trended somewhat positive this week, according to InfoTrie Sentiment. The research firm ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. HTG Molecular Diagnostics earned a coverage optimism score of 0.7 on InfoTrie's scale. They also gave media coverage about the medical research company a news buzz of 7.0 out of 10, indicating that recent media coverage is likely to have an effect on the company's share price in the near future.
Who are some of HTG Molecular Diagnostics' key competitors?
What other stocks do shareholders of HTG Molecular Diagnostics own?
Who are HTG Molecular Diagnostics' key executives?
HTG Molecular Diagnostics' management team includes the folowing people:
- Mr. John L. Lubniewski, Pres, CEO & Director (Age 55)
- Mr. Shaun D. McMeans, Sr. VP of Fin. & Admin., CFO, Sec. & Treasurer (Age 57)
- Dr. Maureen T. Cronin, Sr. VP & Chief Scientific Officer (Age 66)
- Dr. Debra A. Gordon, Sr. VP & Chief Legal Counsel (Age 59)
- Mr. Sam M. Rua Jr., Sr. VP of Regulatory Affairs & Quality Systems (Age 59)
When did HTG Molecular Diagnostics IPO?
(HTGM) raised $50 million in an IPO on Wednesday, May 6th 2015. The company issued 3,600,000 shares at a price of $13.00-$15.00 per share. Leerink Partners acted as the underwriter for the IPO and Canaccord Genuity and JMP Securities were co-managers.
Who are HTG Molecular Diagnostics' major shareholders?
HTG Molecular Diagnostics' stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (11.53%), Perkins Capital Management Inc. (2.17%), National Asset Management Inc. (0.79%), TD Asset Management Inc. (0.34%), BlackRock Inc. (0.23%) and Morgan Stanley (0.20%). Company insiders that own HTG Molecular Diagnostics stock include Holdings A/S Novo and Shaun D Mcmeans. View Institutional Ownership Trends for HTG Molecular Diagnostics.
Which institutional investors are selling HTG Molecular Diagnostics stock?
Which institutional investors are buying HTG Molecular Diagnostics stock?
How do I buy shares of HTG Molecular Diagnostics?
Shares of HTGM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is HTG Molecular Diagnostics' stock price today?
One share of HTGM stock can currently be purchased for approximately $2.18.
How big of a company is HTG Molecular Diagnostics?
HTG Molecular Diagnostics has a market capitalization of $62.44 million and generates $21.50 million in revenue each year. The medical research company earns $-16,450,000.00 in net income (profit) each year or ($0.60) on an earnings per share basis. HTG Molecular Diagnostics employs 107 workers across the globe.
What is HTG Molecular Diagnostics' official website?
How can I contact HTG Molecular Diagnostics?
HTG Molecular Diagnostics' mailing address is 3430 E. GLOBAL LOOP, TUCSON AZ, 85706. The medical research company can be reached via phone at 877-289-2615.
MarketBeat Community Rating for HTG Molecular Diagnostics (NASDAQ HTGM)
MarketBeat's community ratings are surveys of what our community members think about HTG Molecular Diagnostics and other stocks. Vote "Outperform" if you believe HTGM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HTGM will underperform the S&P 500 over the long term. You may vote once every thirty days.
